Pfizer have published data on the discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Filed under: Uncategorized | Tagged: CI-1040, CI1040, MEK, PD-0325901, PD0325901, Pfizer | Comments Off
Pfizer have published data on the discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Filed under: Uncategorized | Tagged: CI-1040, CI1040, MEK, PD-0325901, PD0325901, Pfizer | Comments Off
Pfizer have published a series of trifluoromethylpyrimidine proline-rich tyrosine kinase 2 (PYK2) inhibitors
Filed under: Uncategorized | Tagged: kinase, Pfizer, Preclinical, pyk2, Research | Comments Off
Pfizer have publsihed a series of MEK (MAP ERK Kinase) inhibitors.
Filed under: Uncategorized | Tagged: kinase, MEK, Pfizer, Preclinical, Research | Comments Off
Researchers report that the development of reversible erythrocytosis is a common side effect following the use of sorafenib and sunitiniband may be a class specific adverse effect with all kinase inhibitors
Filed under: kinase | Tagged: kinase, sunitinib, sutent, multikinase, SU11248, SU-11248, Pfizer, Nexavar, sorafenib, onyx, bayer | Comments Off
The UK’s National Institute for Health and Clinical Excellence (NICE) has made a preliminary ruling stating that Avastin, Nexavar, Sutent and ToriselĀ are notĀ effective enough to warrant their high cost and shouldn’t be prescribed to new patients in Britain.
Filed under: Kinase receptor, kinase | Tagged: kinase, sunitinib, sutent, multikinase, SU11248, SU-11248, Pfizer, Genentech, Nexavar, sorafenib, onyx, bayer, VEGF, Wyeth, Roche, Avastin, bevacizumab, mTOR, torisel, temsirolimus, regulatory | Comments Off
Genentech have halted its trial of Avastin in combination with Sutent following reports of several cases of microangiopathic hemolytic anemia (MAHA) in patients with solid tumors
Filed under: kinase | Tagged: Adverse effect, Avastin, bevacizumab, Genentech, kinase, multikinase, Pfizer, Roche, SU-11248, SU11248, sunitinib, sutent, VEGF | Comments Off